CLR 131

Cellectar Biosciences Inc (NASDAQ: CLRB), a nano-cap oncology-focused clinical-stage company, announced on Tuesday a new collaboration to better explore a phase 2 clinical trial. Cellectar selected INC Research Holdings Inc (NASDAQ: INCR), a leading contract research organization, to oversee...